Full Text View
Tabular View
No Study Results Posted
Related Studies
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA)
This study is currently recruiting participants.
Verified December 2011 by Mayo Clinic

First Received on May 28, 2009.   Last Updated on December 2, 2011   History of Changes
Sponsor: Mayo Clinic
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Duke Clinical Research Institute
St. Jude Medical
Biosense Webster, Inc.
Information provided by: Mayo Clinic
ClinicalTrials.gov Identifier: NCT00911508
  Purpose

The CABANA Trial has the overall goal of establishing the appropriate roles for medical and ablative intervention for atrial fibrillation (AF). The CABANA Trial is designed to test the hypothesis that the treatment strategy of left atrial catheter ablation for the purpose of eliminating atrial fibrillation (AF) will be superior to current state-of-the-art therapy with either rate control or rhythm control drugs for reducing total mortality in patients with untreated or incompletely treated AF.


Condition Intervention
Atrial Fibrillation
Arrhythmia
Stroke Prevention
Mortality
 Device: Left atrial ablation
Drug: Rate or Rhythm Control Therapy

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Resource links provided by NLM:

Genetics Home Reference related topics: Brugada syndrome familial atrial fibrillation short QT syndrome
MedlinePlus related topics: Arrhythmia Atrial Fibrillation
U.S. FDA Resources

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Percutaneous left atrial catheter ablation for the purpose of eliminating AF is superior to current state-of-the-art therapy with either rate or rhythm control drugs for reducing total mortality in patients with untreated or incompletely treated AF. [ Time Frame: 6 month intervals, duration of trial ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Decrease the composite endpoint of total mortality, disabling stroke, serious bleeding, and cardiac arrest in patients with untreated or incompletely treated AF warranting therapy. [ Time Frame: 6 month intervals, duration of trial ] [ Designated as safety issue: Yes ]
  • Total mortality, disabling stroke, serious bleeding, or cardiac arrest [ Time Frame: 6 month intervals, length of trial ] [ Designated as safety issue: Yes ]
  • Total mortality or cardiovascular hospitalization [ Time Frame: 6 month intervals, duration of trial ] [ Designated as safety issue: Yes ]
  • Cardiovascular death [ Time Frame: 6 month intervals, length of trial ] [ Designated as safety issue: Yes ]
  • Cardiovascular death or disabling stroke [ Time Frame: 6 month intervals, duration of trial ] [ Designated as safety issue: Yes ]
  • Arrhythmic death or cardiac arrest [ Time Frame: 6 month intervals, duration of trial ] [ Designated as safety issue: Yes ]
  • Heart failure death LA size, morphology and function [ Time Frame: 6 month intervals, duration of trial ] [ Designated as safety issue: Yes ]
  • Freedom from recurrent AF [ Time Frame: Monitored monthly for trial duration ] [ Designated as safety issue: No ]
  • Cardiovascular hospitalization [ Time Frame: 6 month intervals, duration of trial ] [ Designated as safety issue: Yes ]
  • Medical costs, resource utilization, and cost effectiveness [ Time Frame: 6 month intervals, duration of trial ] [ Designated as safety issue: No ]
  • Quality of Life [ Time Frame: At months 3, 6, 12, 18, 24, 30, 36 ] [ Designated as safety issue: No ]
  • Composite adverse events [ Time Frame: 6 month intervals, duration of trial ] [ Designated as safety issue: Yes ]
  • Left atrial size, morphology and function [ Time Frame: Baseline and 3 months post therapy initiation ] [ Designated as safety issue: No ]

Estimated Enrollment: 3000
Study Start Date: August 2009
Estimated Study Completion Date: September 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ablation
Pulmonary vein isolation using a circumferential ablative approach in the left atrium. Ablation may be performed using circular mapping catheter-guided ablation, antral isolation using a circular guided approach, or wide area circumferential ablation.
 Device: Left atrial ablation

St. Jude: Livewire, Therapy Dual/Thermocouple

Biosense Webster: NAVI-STAR Thermo-cool,NAVI-STAR/NAVI-STAR DS, Celsius Braided Tip

CryoCath Technologies: Freezor/Freezor Max

Bard: Stinger

Boston Scientific: Blazer II RF/RPM/SteeroCath/XP, Chilli Cooled.
Active Comparator: Rate or Rhythm Control Therapy
Current state-of-the-art drug therapy for atrial fibrillation (rate control or rhythm control). Treating physicians will be encouraged to follow the American College of Cardiology / American Heart Association / European Society of Cardiology Atrial Fibrillation Guidelines with regard to drug therapy for atrial fibrillation. The specific choice of rate control versus rhythm control drug therapy and the specific drugs to be used will ultimately be left to the discretion of the treating physician.
 Drug: Rate or Rhythm Control Therapy

Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg

Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg

Detailed Description:

The need for this trial arises out of 1) the rapidly increasing number of pts > 60 years of age with AF accompanied by symptoms and morbidity, 2) the failure of anti-arrhythmic drug therapy to maintain sinus rhythm and reduce mortality, 3) the rapidly increasing application of radio-frequency catheter ablation without appropriate evidence-based validation, and 4) the expanding impact of AF on health care costs.

This study will randomize 3000 patients to a strategy of catheter ablation versus pharmacologic therapy with rate or rhythm control drugs. Each pt will have 1) characteristics similar to AFFIRM pts (≥65 yo or <65 with >1 risk factor for stroke, 2) Documented AF warranting treatment, and 3) Eligibility for both catheter ablation and ≥2 anti-arrhythmic or ≥3 rate control drugs. Pts will be followed every 6 months for >2 yrs and will undergo repeat trans-telephonic monitor, Holter monitor, and CT/MR studies to assess the impact of treatment.

The CABANA trial will disclose the role of medical and non-pharmacologic therapies for AF, establish the cost and impact of therapy on quality of life and will help determine if AF is a modifiable risk factor for increased mortality.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have the capacity to understand and sign an informed consent form
  • Be ≥18 years of age.
  • Have documented AF episodes ≥1 hour in duration; with ≥2 episodes over 4 months with electrocardiographic documentation of 1 episode or at least 1 episode of AF lasting more than 1 week
  • Warrant active therapy beyond simple ongoing observation
  • Be eligible for both catheter ablation and ≥2 sequential rhythm control and/or ≥3 rate control drugs.
  • Be ≥65 yrs of age, or <65 yrs with one or more of the following risk factors for stroke: Hypertension, Diabetes, Congestive heart failure, Prior stroke or TIA, LA size ≥5.0 cm (or volume index ≥40 cc/m2), or EF ≥35. Subjects <65 yrs of age whose only risk factor is hypertension must have a second risk factor or LV hypertrophy to qualify.

Exclusion Criteria:

  • Lone AF in the absence of risk factors for stroke in patients <65 years of age
  • Patients who in the opinion of the managing clinician should not yet receive any therapy for AF
  • Patients who have failed ≥2 membrane active anti-arrhythmic drugs at a therapeutic dose due to inefficacy
  • More than one week of amiodarone treatment in the past 3 months
  • An efficacy failure of full dose amiodarone treatment ≥12 weeks duration at any time
  • Reversible causes of AF including thyroid disorders, acute alcohol intoxication, recent major surgical procedures, or trauma
  • Recent cardiac events including MI, PCI, or valve or bypass surgery in the preceding 3 months
  • Hypertrophic obstructive cardiomyopathy
  • Class IV angina or Class IV CHF (including past or planned heart transplantation)
  • Other mandated anti-arrhythmic drug therapy
  • Heritable arrhythmias or increased risk for torsade de pointes with class I or III drugs
  • Prior LA catheter ablation with the intention of treating AF
  • Prior surgical interventions for AF such as the MAZE procedure
  • Prior AV nodal ablation
  • Patients with other arrhythmias requiring ablative therapy
  • Contraindication to warfarin anti-coagulation
  • Renal failure requiring dialysis
  • Medical conditions limiting expected survival to <1 year
  • Women of childbearing potential (unless post-menopausal or surgically sterile)
  • Participation in any other clinical mortality trial
  • Unable to give informed consent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00911508

Contacts
Contact: Kristi H. Monahan, RN, BSM 507-255-6676 CABANA@mayo.edu
Contact: Shari Rolbiecki 507-538-4358 CABANA@mayo.edu

  Show 160 Study Locations
Sponsors and Collaborators
Mayo Clinic
National Heart, Lung, and Blood Institute (NHLBI)
Duke Clinical Research Institute
St. Jude Medical
Biosense Webster, Inc.
Investigators
Principal Investigator: Douglas L. Packer, M.D. Mayo Clinic
Principal Investigator: Kerry L. Lee, Ph.D. Duke Clinical Research Institute
Principal Investigator: Daniel B. Mark, M.D., MPH Duke Clinical Research Institute
Principal Investigator: Rich A. Robb, Ph.D. Phy Mayo Clinic
Study Chair: Alice M. Mascette, M.D. National Heart, Lung, and Blood Institute (NHLBI)
  More Information

Additional Information:
Mayo Clinic Clinical Trials  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Douglas L. Packer, M.D., Mayo Clinic Rochester
ClinicalTrials.gov Identifier: NCT00911508     History of Changes
Other Study ID Numbers: 08-007043 09-004616, U01HL089709
Study First Received: May 28, 2009
Last Updated: December 2, 2011
Health Authority: United States: Food and Drug Administration;   United States: Federal Government

Keywords provided by Mayo Clinic:
Atrial Fibrillation
Left Atrial Ablation
Pulmonary Vein Isolation
Catheter Ablation
Antiarrhythmic Drug Therapy

Additional relevant MeSH terms:
Arrhythmias, Cardiac
Atrial Fibrillation
Stroke
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Cerebrovascular Disorders
Brain Diseases
 Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 09, 2012



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services